Veradermics to present age-subgroup data from VDPHL01 male hair loss trial at AAD Innovation Academy

Veradermics, Incorporated

Veradermics, Incorporated

MANE

0.00
  • Veradermics flagged new age-based subgroup results from Phase 2/3 Study 302 of VDPHL01 in male pattern hair loss.
  • Data were presented July 16, 2026, with an additional oral presentation scheduled July 17, 2026, at the AAD Innovation Academy.
  • Study 302 enrolled over 500 males, testing an extended-release oral minoxidil formulation versus placebo in mild-to-moderate hair loss.
  • Pipeline catalysts include expected topline results from Phase 3 male Study 304 in 2H 2026, female Study 306 in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260717016126) on July 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.